LIVIVO - Search results -

Search results

Result 1 - 10 of total 19

Search options

Book ; Online ; E-Book: Biology and management of unusual plasma cell dyscrasias

Zimmerman, Todd M. / Kumar, Shaji K.

2017

Author's details	Todd M. Zimmerman ; Shaji K. Kumar ed
Language	English
Size	XI, 202 S. : Ill., graph. Darst.
Publisher	Springer
Publishing place	New York
Publishing country	United States
Document type	Book ; Online ; E-Book
Remark	Zugriff für angemeldete ZB MED-Nutzerinnen und -Nutzer
HBZ-ID	HT019098839
ISBN	978-1-4419-6848-7 ; 9781441968470 ; 1-4419-6848-2 ; 1441968474
DOI	10.1007/978-1-4419-6848-7
Database	ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

Full text online

Accessible to users with ZB MED library card

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾
- Full text online
- Order with fees

Book: Biology and management of unusual plasma cell dyscrasias

Zimmerman, Todd M / Kumar, Shaji

2017

Author's details	Todd M. Zimmerman, Shaji K. Kumar, editors
MeSH term(s)	Paraproteinemias/diagnosis ; Paraproteinemias/therapy
Language	English
Size	xi, 202 pages :, illustrations
Document type	Book
ISBN	9781441968470 ; 1441968474 ; 9781441968487 ; 1441968482
Database	Catalogue of the US National Library of Medicine (NLM)

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Regulatory T-cell depletion in the setting of autologous stem cell transplantation for multiple myeloma: pilot study.

Derman, Benjamin A / Zha, Yuanyuan / Zimmerman, Todd M / Malloy, Rebecca / Jakubowiak, Andrzej / Bishop, Michael R / Kline, Justin

Journal for immunotherapy of cancer

2020 Volume 8, Issue 1

Abstract: Background: Progression after high-dose melphalan with autologous stem cell transplantation (ASCT) in multiple myeloma (MM) may be due in part to immune dysfunction. Regulatory T (Treg) cells reconstitute rapidly after ASCT and inhibit immune responses ... ...

Abstract	Background: Progression after high-dose melphalan with autologous stem cell transplantation (ASCT) in multiple myeloma (MM) may be due in part to immune dysfunction. Regulatory T (Treg) cells reconstitute rapidly after ASCT and inhibit immune responses against myeloma cells. Methods: We performed a randomized study to evaluate two methods of Treg depletion in patients with MM undergoing ASCT. No Treg depletion was performed in the control ASCT arm. An anti-CD25 monoclonal antibody (basiliximab 20 mg IV) was administered on day +1 post-ASCT in the in vivo Treg depletion (IVTRD) arm. Tregs were depleted from autologous stem cell (ASC) grafts with anti-CD25 microbeads and the CliniMACS device in the ex vivo Treg depletion (EVTRD) arm. Results: Fifteen patients were enrolled, five in each arm. The conditioning regimen was melphalan 200 mg/m Conclusions: IVTRD and EVTRD are feasible and significantly reduce and delay Treg recovery post-ASCT for MM, and serve as a platform for using post-transplant immunotherapies to improve post-ASCT outcomes. Trial registration number: NCT01526096.
MeSH term(s)	Hematopoietic Stem Cell Transplantation/methods ; Humans ; Middle Aged ; Multiple Myeloma/immunology ; Multiple Myeloma/therapy ; Pilot Projects ; T-Lymphocytes, Regulatory/immunology ; Transplantation, Autologous
Language	English
Publishing date	2020-01-15
Publishing country	England
Document type	Journal Article ; Randomized Controlled Trial ; Research Support, N.I.H., Extramural
ZDB-ID	2719863-7
ISSN	2051-1426 ; 2051-1426
ISSN (online)	2051-1426
ISSN	2051-1426
DOI	10.1136/jitc-2019-000286
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma.

Jagannath, Sundar / Heffner, Leonard T / Ailawadhi, Sikander / Munshi, Nikhil C / Zimmerman, Todd M / Rosenblatt, Jacalyn / Lonial, Sagar / Chanan-Khan, Asher / Ruehle, Markus / Rharbaoui, Faiza / Haeder, Thomas / Wartenberg-Demand, Andrea / Anderson, Kenneth C

Clinical lymphoma, myeloma & leukemia

2019 Volume 19, Issue 6, Page(s) 372–380

Abstract: Background: Indatuximab ravtansine (BT062) is an antibody-drug conjugate that binds to CD138, which is overexpressed on multiple myeloma (MM) cells.: Patients and methods: We report from 2 clinical studies of patients with relapsed and/or refractory ... ...

Abstract	Background: Indatuximab ravtansine (BT062) is an antibody-drug conjugate that binds to CD138, which is overexpressed on multiple myeloma (MM) cells. Patients and methods: We report from 2 clinical studies of patients with relapsed and/or refractory MM previously treated with an immunomodulatory drug and a proteasome inhibitor. Single- and multi-dosing schedules were investigated to define dose-limiting toxicities, maximum tolerated dose (MTD), recommended phase II dose, and to describe safety, efficacy, and pharmacokinetics. Results: In the first-in-human study, indatuximab ravtansine was administered to 32 patients on day 1 of each 21-day cycle. The MTD was 160 mg/m Conclusion: Our data support further investigation of indatuximab ravtansine as part of a combination regimen for relapsed and/or refractory MM.
MeSH term(s)	Adult ; Aged ; Antineoplastic Agents, Immunological/administration & dosage ; Antineoplastic Agents, Immunological/adverse effects ; Antineoplastic Agents, Immunological/therapeutic use ; Drug Resistance, Neoplasm ; Female ; Humans ; Immunoconjugates/administration & dosage ; Immunoconjugates/adverse effects ; Immunoconjugates/therapeutic use ; Male ; Maytansine/administration & dosage ; Maytansine/adverse effects ; Maytansine/analogs & derivatives ; Maytansine/therapeutic use ; Middle Aged ; Multiple Myeloma/diagnosis ; Multiple Myeloma/drug therapy ; Multiple Myeloma/mortality ; Neoplasm Grading ; Neoplasm Staging ; Recurrence ; Treatment Outcome
Chemical Substances	Antineoplastic Agents, Immunological ; Immunoconjugates ; indatuximab ravtansine ; Maytansine (14083FR882)
Language	English
Publishing date	2019-02-21
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2540992-X
ISSN	2152-2669 ; 2152-2650
ISSN (online)	2152-2669
ISSN	2152-2650
DOI	10.1016/j.clml.2019.02.006
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5903: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study.

The Lancet. Haematology

2021 Volume 8, Issue 11, Page(s) e794–e807

Abstract: Background: Indatuximab ravtansine (BT062) is an antibody-drug conjugate that binds to CD138 and synergistically enhances the antitumor activity of lenalidomide in preclinical models of multiple myeloma. This phase 1/2a study was done to determine the ... ...

Abstract	Background: Indatuximab ravtansine (BT062) is an antibody-drug conjugate that binds to CD138 and synergistically enhances the antitumor activity of lenalidomide in preclinical models of multiple myeloma. This phase 1/2a study was done to determine the safety, activity, and pharmacokinetics of indatuximab ravtansine in combination with immunomodulatory drugs in patients with relapsed or refractory multiple myeloma. Methods: This open-label, phase 1/2a study took place at nine hospital sites in the USA. Eligible patients were aged 18 years or older, had relapsed or refractory multiple myeloma, and ECOG performance status or Zubrod score of 2 or below. Patients who received indatuximab ravtansine with lenalidomide and dexamethasone (indatuximab ravtansine plus lenalidomide) had failure of at least one previous therapy. Patients treated with indatuximab ravtansine with pomalidomide and dexamethasone (indatuximab ravtansine plus pomalidomide) had failure of at least two previous therapies (including lenalidomide and bortezomib) and had progressive disease on or within 60 days of completion of their last treatment. In phase 1, patients received indatuximab ravtansine intravenously on days 1, 8, and 15 of each 28-day cycle in escalating dose levels of 80 mg/m Findings: 64 (86%) of 74 screened patients were enrolled between July 3, 2012, and June 30, 2015. 47 (73%) patients received indatuximab ravtansine plus lenalidomide (median follow-up 24·2 months [IQR 19·9-45·4]) and 17 (27%) received indatuximab ravtansine plus pomalidomide (24·1 months [17·7-36·7]). The maximum tolerated dose of indatuximab ravtansine plus lenalidomide was 100 mg/m Interpretation: Indatuximab ravtansine in combination with immunomodulatory drugs shows preliminary antitumor activity, is tolerated, and could be further evaluated in patients with relapsed or refractory multiple myeloma. Funding: Biotest AG.
MeSH term(s)	Adult ; Aged ; Aged, 80 and over ; Angiogenesis Inhibitors/adverse effects ; Angiogenesis Inhibitors/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Dexamethasone/adverse effects ; Dexamethasone/therapeutic use ; Female ; Humans ; Immunoconjugates/adverse effects ; Immunoconjugates/therapeutic use ; Lenalidomide/adverse effects ; Lenalidomide/therapeutic use ; Male ; Maximum Tolerated Dose ; Maytansine/adverse effects ; Maytansine/analogs & derivatives ; Maytansine/therapeutic use ; Middle Aged ; Multiple Myeloma/drug therapy ; Neoplasm Recurrence, Local/drug therapy ; Thalidomide/adverse effects ; Thalidomide/analogs & derivatives ; Thalidomide/therapeutic use
Chemical Substances	Angiogenesis Inhibitors ; Immunoconjugates ; indatuximab ravtansine ; Maytansine (14083FR882) ; Thalidomide (4Z8R6ORS6L) ; Dexamethasone (7S5I7G3JQL) ; pomalidomide (D2UX06XLB5) ; Lenalidomide (F0P408N6V4)
Language	English
Publishing date	2021-09-13
Publishing country	England
Document type	Clinical Trial, Phase I ; Clinical Trial, Phase II ; Journal Article ; Multicenter Study
ISSN	2352-3026
ISSN (online)	2352-3026
DOI	10.1016/S2352-3026(21)00208-8
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma.

Jakubowiak, Andrzej J / Jasielec, Jagoda K / Rosenbaum, Cara A / Cole, Craig E / Chari, Ajai / Mikhael, Joseph / Nam, Jennifer / McIver, Amanda / Severson, Erica / Stephens, Leonor A / Tinari, Kathryn / Rosebeck, Shaun / Zimmerman, Todd M / Hycner, Tyler / Turowski, Agata / Karrison, Theodore / Zonder, Jeffrey A

British journal of haematology

2019 Volume 186, Issue 4, Page(s) 549–560

Abstract: Selinexor, an oral Selective Inhibitor of Nuclear Export, targets Exportin 1 (XPO1, also termed CRM1). Non-clinical studies support combining selinexor with proteasome inhibitors (PIs) and corticosteroids to overcome resistance in relapsed/refractory ... ...

Abstract	Selinexor, an oral Selective Inhibitor of Nuclear Export, targets Exportin 1 (XPO1, also termed CRM1). Non-clinical studies support combining selinexor with proteasome inhibitors (PIs) and corticosteroids to overcome resistance in relapsed/refractory multiple myeloma (RRMM). We conducted a phase I dose-escalation trial of twice-weekly selinexor in combination with carfilzomib and dexamethasone (SKd) to determine maximum tolerated dose in patients with RRMM (N = 21), with an expansion cohort to assess activity in carfilzomib-refractory disease and identify a recommended phase II dose (RP2D). During dose escalation, there was one dose-limiting toxicity (cardiac failure). The RP2D of twice-weekly SKd was selinexor 60 mg, carfilzomib 20/27 mg/m
MeSH term(s)	Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Cytogenetic Analysis ; Dexamethasone/administration & dosage ; Drug Resistance, Neoplasm ; Female ; Humans ; Hydrazines/administration & dosage ; Male ; Middle Aged ; Multiple Myeloma/drug therapy ; Multiple Myeloma/mortality ; Multiple Myeloma/pathology ; Neoplasm Staging ; Oligopeptides/administration & dosage ; Prognosis ; Recurrence ; Retreatment ; Treatment Outcome ; Triazoles/administration & dosage
Chemical Substances	Hydrazines ; Oligopeptides ; Triazoles ; selinexor (31TZ62FO8F) ; carfilzomib (72X6E3J5AR) ; Dexamethasone (7S5I7G3JQL)
Language	English
Publishing date	2019-05-24
Publishing country	England
Document type	Clinical Trial, Phase I ; Journal Article ; Multicenter Study ; Research Support, Non-U.S. Gov't
ZDB-ID	80077-6
ISSN	1365-2141 ; 0007-1048
ISSN (online)	1365-2141
ISSN	0007-1048
DOI	10.1111/bjh.15969
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Uh III Zs.182: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma.

Blood

2020 Volume 136, Issue 22, Page(s) 2513–2523

Abstract: In this phase 2 multicenter study, we evaluated the incorporation of autologous stem cell transplantation (ASCT) into a carfilzomib-lenalidomide-dexamethasone (KRd) regimen for patients with newly diagnosed multiple myeloma (NDMM). Transplant-eligible ... ...

Abstract	In this phase 2 multicenter study, we evaluated the incorporation of autologous stem cell transplantation (ASCT) into a carfilzomib-lenalidomide-dexamethasone (KRd) regimen for patients with newly diagnosed multiple myeloma (NDMM). Transplant-eligible patients with NDMM received 4 cycles of KRd induction, ASCT, 4 cycles of KRd consolidation, and 10 cycles of KRd maintenance. The primary end point was rate of stringent complete response (sCR) after 8 cycles of KRd with a predefined threshold of ≥50% to support further study. Seventy-six patients were enrolled with a median age of 59 years (range, 40-76 years), and 35.5% had high-risk cytogenetics. The primary end point was met, with an sCR rate of 60% after 8 cycles. Depth of response improved over time. On intent-to-treat (ITT), the sCR rate reached 76%. The rate of minimal residual disease (MRD) negativity using modified ITT was 70% according to next-generation sequencing (<10-5 sensitivity). After median follow-up of 56 months, 5-year progression-free survival (PFS) and overall survival (OS) rates were 72% and 84% for ITT, 85% and 91% for MRD-negative patients, and 57% and 72% for patients with high-risk cytogenetics. For high-risk patients who were MRD negative, 5-year rates were 77% and 81%. Grade 3 to 4 adverse events included neutropenia (34%), lymphopenia (32%), infection (22%), and cardiac events (3%). There was no grade 3 to 4 peripheral neuropathy. Patients with NDMM treated with KRd with ASCT achieved high rates of sCR and MRD-negative disease at the end of KRd consolidation. Extended KRd maintenance after consolidation contributed to deepening of responses and likely to prolonged PFS and OS. Safety and tolerability were manageable. This trial was registered at www.clinicaltrials.gov as #NCT01816971.
MeSH term(s)	Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Autografts ; Dexamethasone/administration & dosage ; Dexamethasone/adverse effects ; Disease-Free Survival ; Female ; Hematopoietic Stem Cell Transplantation ; Humans ; Lenalidomide/administration & dosage ; Lenalidomide/adverse effects ; Male ; Middle Aged ; Multiple Myeloma/diagnosis ; Multiple Myeloma/mortality ; Multiple Myeloma/therapy ; Oligopeptides/administration & dosage ; Oligopeptides/adverse effects ; Progression-Free Survival
Chemical Substances	Oligopeptides ; carfilzomib (72X6E3J5AR) ; Dexamethasone (7S5I7G3JQL) ; Lenalidomide (F0P408N6V4)
Language	English
Publishing date	2020-07-31
Publishing country	United States
Document type	Clinical Trial, Phase II ; Journal Article ; Multicenter Study ; Research Support, Non-U.S. Gov't
ZDB-ID	80069-7
ISSN	1528-0020 ; 0006-4971
ISSN (online)	1528-0020
ISSN	0006-4971
DOI	10.1182/blood.2020007522
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.140: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 364: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1.

Richardson, Paul G / Zimmerman, Todd M / Hofmeister, Craig C / Talpaz, Moshe / Chanan-Khan, Asher A / Kaufman, Jonathan L / Laubach, Jacob P / Chauhan, Dharminder / Jakubowiak, Andrzej J / Reich, Steven / Trikha, Mohit / Anderson, Kenneth C

Blood

2016 Volume 127, Issue 22, Page(s) 2693–2700

Abstract: Marizomib (MRZ) is a novel, irreversible proteasome inhibitor in clinical development for the treatment of relapsed or relapsed and refractory multiple myeloma (RRMM). MRZ inhibits the 3 proteolytic activities of the 20S proteasome with specificity ... ...

Abstract	Marizomib (MRZ) is a novel, irreversible proteasome inhibitor in clinical development for the treatment of relapsed or relapsed and refractory multiple myeloma (RRMM). MRZ inhibits the 3 proteolytic activities of the 20S proteasome with specificity distinct from bortezomib and carfilzomib. Study NPI-0052-101 Part 1 enrolled relapsed or RRMM patients into an open-label, dose-escalation design to determine the maximum tolerated dose and recommended phase 2 dose (RP2D) of MRZ administered intravenously on 2 different schedules: schedule A (0.025-0.7 mg/m(2) once weekly on days 1, 8, and 15 of 4-week cycles) and schedule B (0.15-0.6 mg/m(2) twice weekly on days 1, 4, 8, and 11 of 3-week cycles; concomitant dexamethasone was allowed with schedule B). Patients had received an average of 4.9 and 7.3 prior treatment regimens (schedules A and B, respectively). MRZ schedule A was administered to 32 patients, and the RP2D was established as 0.7 mg/m(2) infused over 10 minutes. Schedule B was administered to 36 patients, and the RP2D was determined to be 0.5 mg/m(2) infused over 2 hours. The most common (>20% of patients) related adverse events were fatigue, headache, nausea, diarrhea, dizziness, and vomiting. Six patients achieved clinical benefit responses (defined as minimal response or better), including 5 partial responses (1 patient on schedule A and 4 on schedule B; 3 of these 4 patients received concomitant dexamethasone). MRZ was generally well tolerated, and results suggest activity in previously treated RRMM patients. Combination studies using pomalidomide and dexamethasone are now underway. The trial was registered at www.clinicaltrials.gov as #NCT00461045.
MeSH term(s)	Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Dexamethasone/administration & dosage ; Dexamethasone/adverse effects ; Female ; Humans ; Lactones/administration & dosage ; Lactones/adverse effects ; Male ; Maximum Tolerated Dose ; Middle Aged ; Multiple Myeloma/drug therapy ; Multiple Myeloma/mortality ; Pyrroles/administration & dosage ; Pyrroles/adverse effects ; Recurrence ; Thalidomide/administration & dosage ; Thalidomide/adverse effects ; Thalidomide/analogs & derivatives
Chemical Substances	Lactones ; Pyrroles ; Thalidomide (4Z8R6ORS6L) ; marizomib (703P9YDP7F) ; Dexamethasone (7S5I7G3JQL) ; pomalidomide (D2UX06XLB5)
Language	English
Publishing date	2016-03-23
Publishing country	United States
Document type	Clinical Trial, Phase I ; Journal Article ; Multicenter Study ; Research Support, Non-U.S. Gov't
ZDB-ID	80069-7
ISSN	1528-0020 ; 0006-4971
ISSN (online)	1528-0020
ISSN	0006-4971
DOI	10.1182/blood-2015-12-686378
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.140: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 364: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma.

Kumar, Shaji K / Bensinger, William I / Zimmerman, Todd M / Reeder, Craig B / Berenson, James R / Berg, Deborah / Hui, Ai-Min / Gupta, Neeraj / Di Bacco, Alessandra / Yu, Jiang / Shou, Yaping / Niesvizky, Ruben

Blood

2014 Volume 124, Issue 7, Page(s) 1047–1055

Abstract: Proteasome inhibition is an effective treatment strategy for multiple myeloma. With improving survival, attention is increasingly focusing on ease of administration and toxicity profile. Ixazomib is an investigational, orally bioavailable 20S proteasome ... ...

Abstract	Proteasome inhibition is an effective treatment strategy for multiple myeloma. With improving survival, attention is increasingly focusing on ease of administration and toxicity profile. Ixazomib is an investigational, orally bioavailable 20S proteasome inhibitor. Sixty patients with relapsed and/or refractory multiple myeloma were enrolled on this phase 1 trial to evaluate safety and tolerability and determine the maximum tolerated dose (MTD) of single-agent, oral ixazomib given weekly for 3 of 4 weeks. Upon MTD determination, patients were enrolled to 4 different cohorts based on relapsed/refractory status and prior bortezomib and carfilzomib exposure. The MTD was determined to be 2.97 mg/m(2). Dose-limiting toxicities were grade 3 nausea, vomiting, and diarrhea in 2 patients, and grade 3 skin rash in 1 patient. Common drug-related adverse events were thrombocytopenia (43%), diarrhea (38%), nausea (38%), fatigue (37%), and vomiting (35%). The observed rate of peripheral neuropathy was 20%, with only 1 grade 3 event reported. Nine (18%) patients achieved a partial response or better, including 8 of 30 (27%) evaluable patients treated at the MTD. Pharmacokinetic studies suggested a long terminal half-life of 3.6 to 11.3 days, supporting once-weekly dosing. This trial was registered at www.clinicaltrials.gov as #NCT00963820.
MeSH term(s)	Administration, Oral ; Adult ; Aged ; Area Under Curve ; Boron Compounds/adverse effects ; Boron Compounds/pharmacokinetics ; Boron Compounds/therapeutic use ; Diarrhea/chemically induced ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Drug Resistance, Neoplasm/drug effects ; Drugs, Investigational/adverse effects ; Drugs, Investigational/pharmacokinetics ; Drugs, Investigational/therapeutic use ; Fatigue/chemically induced ; Female ; Glycine/adverse effects ; Glycine/analogs & derivatives ; Glycine/pharmacokinetics ; Glycine/therapeutic use ; Humans ; Male ; Middle Aged ; Multiple Myeloma/drug therapy ; Nausea/chemically induced ; Neoplasm Recurrence, Local ; Proteasome Inhibitors/adverse effects ; Proteasome Inhibitors/pharmacokinetics ; Proteasome Inhibitors/therapeutic use ; Remission Induction ; Thrombocytopenia/chemically induced ; Treatment Outcome ; Vomiting/chemically induced
Chemical Substances	Boron Compounds ; Drugs, Investigational ; Proteasome Inhibitors ; ixazomib (71050168A2) ; Glycine (TE7660XO1C)
Language	English
Publishing date	2014-06-05
Publishing country	United States
Document type	Clinical Trial, Phase I ; Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	80069-7
ISSN	1528-0020 ; 0006-4971
ISSN (online)	1528-0020
ISSN	0006-4971
DOI	10.1182/blood-2014-01-548941
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.140: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 364: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Lenalidomide for the treatment of cryoglobulinemia and undifferentiated spondyloarthropathy in a patient with multiple myeloma.

Lin, Richard J / Curran, James J / Zimmerman, Todd M / Song, Jie / Niewold, Timothy B / Sweiss, Nadera J

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases

2010 Volume 16, Issue 2, Page(s) 90–91

MeSH term(s)	Adult ; Antineoplastic Agents/therapeutic use ; Cryoglobulinemia/complications ; Cryoglobulinemia/drug therapy ; HLA-B27 Antigen/analysis ; Humans ; Lenalidomide ; Lumbar Vertebrae ; Male ; Multiple Myeloma/complications ; Sacroiliac Joint ; Spondylarthropathies/complications ; Spondylarthropathies/drug therapy ; Thalidomide/analogs & derivatives ; Thalidomide/therapeutic use
Chemical Substances	Antineoplastic Agents ; HLA-B27 Antigen ; Thalidomide (4Z8R6ORS6L) ; Lenalidomide (F0P408N6V4)
Language	English
Publishing date	2010-02-01
Publishing country	United States
Document type	Case Reports ; Journal Article
ZDB-ID	1283266-2
ISSN	1536-7355 ; 1076-1608
ISSN (online)	1536-7355
ISSN	1076-1608
DOI	10.1097/RHU.0b013e3181d0bfef
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4815: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

Full text online

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito